Published in J Immunol on January 15, 2006
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
Immunosenescence of ageing. J Pathol (2007) 3.32
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol (2010) 2.67
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 2.46
The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev (2009) 1.70
The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol (2009) 1.39
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Cellular vaccine approaches. Cancer J (2010) 1.27
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One (2012) 1.10
Factors that may impact on immunosenescence: an appraisal. Immun Ageing (2010) 1.09
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol (2009) 1.03
New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol (2011) 0.99
Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res (2009) 0.99
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
Whole cell vaccines--past progress and future strategies. Semin Oncol (2012) 0.93
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clin Cancer Res (2015) 0.92
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs (2008) 0.87
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer (2009) 0.83
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood (2014) 0.82
Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res (2014) 0.81
Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer (2013) 0.81
Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81
Preclinical HER-2 Vaccines: From Rodent to Human HER-2. Front Oncol (2013) 0.80
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity. PLoS One (2013) 0.78
Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother (2014) 0.78
Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. Transplantation (2015) 0.78
OX40 signaling directly triggers the antitumor effects of NKT cells. J Clin Invest (2007) 0.78
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res (2017) 0.76
Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. J Immunol (2016) 0.76
Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes (2016) 0.75
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. Front Immunol (2017) 0.75
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res (2007) 2.71
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park) (2013) 2.29
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One (2011) 1.79
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A (2002) 1.77
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer (2005) 1.74
Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J Virol (2002) 1.73
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci U S A (2005) 1.68
Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res (2005) 1.68
Circulating vascular growth factors and central hemodynamic load in the community. Hypertension (2012) 1.56
Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.55
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res (2012) 1.48
A plastic surgery application in evolution: three-dimensional printing. Plast Reconstr Surg (2014) 1.46
Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol (2002) 1.41
Ductal access for prevention and therapy of mammary tumors. Cancer Res (2006) 1.38
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother (2015) 1.35
Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene (2005) 1.35
Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci (2008) 1.33
Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol (2005) 1.33
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 1.32
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest (2008) 1.28
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res (2009) 1.28
Cellular vaccine approaches. Cancer J (2010) 1.27
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol (2003) 1.25
Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol (2002) 1.24
Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev (2005) 1.21
Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol (2007) 1.15
Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen (2009) 1.11
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol (2010) 1.11
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem (2004) 1.10
Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J (2009) 1.10
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One (2012) 1.10
Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther (2003) 1.09
Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res (2003) 1.07
Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells. Infect Immun (2011) 1.05
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res (2008) 1.04
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis (2012) 1.03
Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin. J Biol Chem (2005) 1.03
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. Transl Oncol (2012) 1.01
Cancer vaccines: an old idea comes of age. Cancer Biol Ther (2003) 1.00
HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model. Plast Reconstr Surg (2012) 1.00
GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med (2010) 1.00
Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res (2007) 0.99
Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. J Infect Dis (2012) 0.99
Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol (2011) 0.99
Immune targeting in breast cancer. Oncology (Williston Park) (2015) 0.99
Rofecoxib, Merck, and the FDA. N Engl J Med (2004) 0.99
Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res (2005) 0.98
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. Int Immunopharmacol (2010) 0.97
Targeted reinnervation for transhumeral amputees: current surgical technique and update on results. Plast Reconstr Surg (2009) 0.97
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat (2011) 0.97
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp (2013) 0.97
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine (2007) 0.97
An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res (2008) 0.96